Novartis’ breast cancer drug ribociclib gets US, EU review

Novartis' experimental selective cyclin dependent kinase inhibitor LEE011 (ribociclib) is now under review on both sides of the Atlantic as a potential treatment for breast cancer.
Read the full story: PharmaTimes: News RSS